HR+/HER2- metastatic breast cancer
Clinical trials for HR+/HER2- metastatic breast cancer explained in plain language.
Never miss a new study
Get alerted when new HR+/HER2- metastatic breast cancer trials appear
Sign up with your email to follow new studies for HR+/HER2- metastatic breast cancer, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Can a common breast cancer drug work equally well in underrepresented groups?
Knowledge-focused CompletedThis study looks back at medical records to see how ribociclib, a CDK4/6 inhibitor used for hormone receptor-positive, HER2-negative metastatic breast cancer, is prescribed and tolerated in older adults (65 and over) and Black/African American patients. These groups are often und…
Matched conditions: HR+/HER2- METASTATIC BREAST CANCER
Sponsor: Novartis Pharmaceuticals • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Real-World study tracks palbociclib use in canadian breast cancer patients
Knowledge-focused CompletedThis study observes how Canadian women with a specific type of advanced breast cancer (HR+/HER2-) use the drug palbociclib (Ibrance) as their first treatment. Researchers will measure how long patients stay on the drug and look at treatment patterns in real-world settings, outsid…
Matched conditions: HR+/HER2- METASTATIC BREAST CANCER
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
Real-World study reveals Palbociclib's impact on breast cancer in africa and middle east
Knowledge-focused CompletedThis study looked at 185 people with a common type of advanced breast cancer (HR+/HER2-) in Africa and the Middle East who were starting treatment with palbociclib combined with hormone therapy. Researchers tracked how long the cancer stayed under control and how patients felt ov…
Matched conditions: HR+/HER2- METASTATIC BREAST CANCER
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:06 UTC
-
Gulf study reveals Real-World use of palbociclib for advanced breast cancer
Knowledge-focused CompletedThis completed study looked at medical records of 258 adults in Saudi Arabia, UAE, and other Gulf countries who received palbociclib (a targeted cancer pill) combined with hormone therapy for advanced HR+/HER2- breast cancer. Researchers aimed to describe patient characteristics,…
Matched conditions: HR+/HER2- METASTATIC BREAST CANCER
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
What breast cancer patients really think about their treatment
Knowledge-focused CompletedThis study interviewed 48 adults with HR+/HER2- metastatic breast cancer who had taken capivasertib + fulvestrant for at least one week. The goal was to learn about their attitudes, experiences, and any side effects related to the treatment schedule. No new drugs were given; it w…
Matched conditions: HR+/HER2- METASTATIC BREAST CANCER
Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
New study sheds light on best treatment for older breast cancer patients
Knowledge-focused CompletedThis study looked at medical records of 779 older adults (65+) with a certain type of advanced breast cancer (HR+/HER2-). It compared survival in those who received a combination of the drug palbociclib plus hormone therapy versus hormone therapy alone. The goal was to see which …
Matched conditions: HR+/HER2- METASTATIC BREAST CANCER
Sponsor: Pfizer • Aim: Knowledge-focused
Last updated Jun 27, 2026 07:58 UTC